Sunday

Long-term impact of interferon or Copaxone (Glatiramer acetate) in MS: A systematic review and meta-analysis

›
Image Source: ISRAELVALLEY

Teva and Active Biotech Announce Discontinuation of Higher Doses of Copaxone (Laquinimod) in Two MS Trials

›
Image Source: 43 RUMORS CONCERTO and ARPEGGIO Trials Continue Study of Lower-dose Laquinimod Jerusalem & Lund, Sw...

Estriol combined with Copaxone (glatiramer acetate) for women with relapsing-remitting MS a randomised, placebo-controlled, phase 2 trial: STUDY

›
Image Source: PINTEREST

A randomized trial of Aubagio (teriflunomide) added to Copaxone (glatiramer acetate) in relapsing MS

›
Image Source: BING

End-of-Year Task: Renewing Your DMT Prescription for 2016

›
By Kim Dolce—December 8, 2015 December is upon us, and besides being the holiday season, ‘tis also the seas...

Relapsing MS Treatment Now Available in Japan

›
Copaxone, marketed by Takeda, is already approved for use in some 50 countries Takeda Pharmaceutical Co. Ltd....

The Effect of Three Times a Week Copaxone (Glatiramer Acetate) on Cerebral T1 Hypointense Lesions in Relapsing-Remitting MS: STUDY

›
Image Source: ISRAELVALLEY

Teva Pharmaceutical Industries’ COPAXONE 40 mg/mL Three-times-a-week Approved in Russia for Relapsing-Remitting MS

›
Image Source: THECAREFREETRAVELER Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company that ...

Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to Copaxone (glatiramer acetate): STUDY

›
ISRAELVALLEY

Mylan Confirms Continued Patent Proceedings Concerning MS Therapy Copaxone

›
Image Source: ISRAELVALLEY According to a press release from Mylan N.V., the U.S. Patent and Trademark Office (PTO...

Tolerability and Safety of Combined Copaxone (Glatiramer Acetate) and N-Acetylcysteine in Relapsing-Remitting MS: STUDY

›
Image source: PREVENTDISEASE
Thursday

First generic multiple sclerosis drug, made in Cambridge, launches

›
Image source: DRUGDISCOVERY Cambridge-based Momenta Pharmaceuticals and partner Sandoz announced plans late yesterday...

GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of Copaxone (glatiramer acetate) 40 mg/ml three-times weekly versus 20 mg/ml daily in patients with relapsing-remitting multiple sclerosis: STUDY

›
Image source: PHARMAFILE

Relief for Natco: US court junks Teva’s patent on Copaxone

›
In a relief to Natco Pharma, the US court of appeals has invalidated Teva’s Copaxone patent. This may help generic ph...

Teva Ruling Clears Way for Generic Version of Multiple Sclerosis Drug

›
Image source: UCRTODAY The first generic version of a multiple sclerosis drug went on the market Thursday, hours ...

Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with Copaxone (glatiramer acetate)

›
Image source: MYELITETMOI
Sunday

Patient experience with Copaxone (glatiramer acetate) 40 mg/1 mL three-times weekly treatment for relapsing-remitting multiple sclerosis: Results from the GLACIER extension study: STUDY

›

Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disability: STUDY

›

Comparison of Relapse Rates in Multiple Sclerosis Patients Switching from Glatiramer Acetate (Copaxone) to Fingolimod (Gilenya) versus Those Remaining on Glatiramer Acetate: STUDY

›

FDA approves first generic Copaxone to treat multiple sclerosis

›
The U.S. Food and Drug Administration has approved the first generic version of Copaxone (glatiramer acet...

Teva shares slide on generic Copaxone fears

›
A sign bearing the logo of Teva Pharmaceutical Industries is seen in its Jerusalem oral solid dosage plant (OSD) De...
Wednesday

FREE MS RESEARCH UPDATE: a comprehensive overview of research findings on all of the FDA-approved disease-modifying therapies, as well as many experimental treatments

›
This year's expanded MS Research Update incorporates new information about the approved disease-modifying therapies (DMTs), as well as...
Sunday

3 Blockbuster Drugs That May Be Obsolete in 5 Years

›
Blockbuster status is the Holy Grail for drug developers, but patent expirations mean these billion-dollar drugs have a limit...

Teva sees generic Copaxone competition on horizon

›
Foreign exchange rates and generic competition for its multiple sclerosis blockbuster Copaxone has led Teva Pharmac...

Comparative effectiveness of Copaxone (glatiramer acetate) and interferon beta formulations in relapsing–remitting multiple sclerosis: STUDY

›

Impact of a switch to Gilenya (fingolimod) versus staying on Copaxone (glatiramer acetate) or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial: STUDY

›

Multiple sclerosis market is arguably one of the most competitive in pharma

›
The multiple sclerosis market is arguably one of the most competitive in pharma, shaped in part by a handful o...
Wednesday

Lawbreaker: MULTIPLE SCLEROSIS GOES CRIMINAL (by Yvonne deSousa)

›
When I typed the title of this blog post I was saying to myself, laaaaaawwwww breaker, using a Matthew McConaughey legal thriller voice....

Generic Glatiramer, Cannabis Product Advance for MS

›
A lower-cost version of one of the mainstays of first-line multiple sclerosis treatment appears poised to win mark...

Teva and Active Biotech Announce Expansion of Laquinimod Clinical Development Program with New Trial in Primary Progressive Multiple Sclerosis and First Patient Screened in Huntington's Disease Trial

›
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) today announced...

Is It Time to Buy Dividend Stock Teva Pharmaceutical Industries Ltd?

›
Dividend stocks are a pivotal part of a balanced portfolio because they provide income and can help to lower the ...

Joint ACTRIMS-ECTRIMS Meeting Underscore Teva Pharmaceutical Industries Limited (TEVA)’s Commitment To Developing Solutions To Meet The Needs Of The Multiple Sclerosis Community

›
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that more than 20 company-sponsored abstracts including data ...

Expanded Data on Disability and Cognitive Improvements in Phase II Study of Synthetic Biologics' Trimesta in Multiple Sclerosis to be Presented at 2014 Joint ACTRIMS-ECTRIMS Meeting

›
Dr. Rhonda Voskuhl, M.D. Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective b...
Sunday

US multiple sclerosis market is expected to evolve notably in 2014

›
The US multiple sclerosis market is expected to evolve notably in 2014, with analysts now confident that the FDA will appr...

Pregnant hormone can reduce MS symptoms

›
The hormone is a form of estrogen called estriol. It's abundant in a woman's body only when she is pregnant. Adding...

EU again turns down Teva's laquinimod

›
Teva and Active Biotech filed a request for a review of the finding. The result is a setback for the two companies. Laquinimod has been cons...

Teva keeps the faith after another rebuke for Copaxone's MS heir: Laquinimod

›

Lemtrada offers new hope for MSers living in Canada - Video

›

Comparative effectiveness of Copaxone (glatiramer acetate) and interferon beta formulations in relapsing–remitting multiple sclerosis: STUDY

›

Impact of a switch to Gilenya (fingolimod) versus staying on Copaxone (glatiramer acetate) or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial: STUDY

›

Copaxone FDA Review Slugfest Leaves Investors Fuzzy

›
Teva is stubbornly defending its blockbuster multiple sclerosis drug Copaxone, talking up gene expression data and the safety...

Data To Be Presented At MS Boston 2014: Joint ACTRIMS-ECTRIMS Meeting Underscore Teva Pharmaceutical Industries Limited (TEVA)s Commitment To Developing Solutions To Meet The Needs Of The MS Community

›
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that more than 20 company-spo...

Oral Drug Stalls Clinically Definite MS

›
COPENHAGEN -- Teriflunomide (Aubagio) significantly reduced the risk of clinically definite multiple sclerosis in patients who had suffered ...

Latest Comments From Subject Time Posted

›
Latest Comments From Subject Time Posted 1 NEW! » Jeannine Elan Extends Tysabri's Reach to Canada Oct 8 2006 07:46 1 NEW! » Jeannine ...

Press Release: Surveyed U.S. Neurologists Would be Willing to Accept a Novel Primary-Progressive Multiple Sclerosis Therapy with Safety Risk if Proven Effective on Disability Progression

›
BURLINGTON, Mass. ,  April 8, 2014  /PRNewswire/ -- Decision Resources Group (DRG) finds that, for the treatment of primary-progressive mult...

U.S. Supreme Court agrees to hear patent case that could impact timing of availability of more affordable generic copaxone

›
The United States Supreme Court has granted certiorari in a patent case that could extend the market exclusivity of a top-...

WOW!! READ DEBBIE'S WONDERFUL NEWS ABOUT GILENYA!!! SHE'S BEEN ON IT FOR A YEAR & ITS HELPING HER WIN HER FIGHT AGAINST MULTIPLE SCLEROSIS!

›
SHE'S BEEN ON IT FOR A YEAR & ITS HELPING HER WIN HER FIGHT AGAINST MULTIPLE SCLEROSIS! It has been now exactly a year since I st...
Friday

Wow! It's no wonder MS is seen as a Cash Cow: THESE MS DRUGS BROUGHT IN THE MOST MONEY LAST YEAR

›
Teva soaring out in front on a single product and it is no surprise that the Generics pack are waiting in the rear ready for the copaxone p...

Copaxone lipoatrophy far more common than reported: he risk of lipoatrophy with glatiramer acetate is greater than 60%

›
The risk is "substantially higher than previously reported and [is] often the sole factor prompting patients to switch to another MS [d...

85 STORIES & STUDIES HAVE BEEN POSTED IN MARCH'S NEWS SO FAR

›
"It takes about 2 x as long for someone with MS to absorb and process information as someone who does not have MS: Back to School With...

CLICK HERE AND READ THEM PLUS OTHERS WE WILL BE POSTING!! LOTS OF EXCITING NEWS FOR MSers!!:

›
CLICK HERE AND READ THEM PLUS OTHERS WE WILL BE POSTING!! LOTS OF EXCITING NEWS FOR MSers!!: www.MSnewsChannel.com ECTRIMS: TYSABRI Use ...

!!!!! LEAD...DEE COLUMN

›
I Listened to ME!  Was I right...was I wrong! Living with MS 37 years, having 3 Neuro's, diagnosed in a time there were no ABC drugs, ...

Teva Pharmaceutical Industries Ltd. Gets a Taste of its Own Medicine

›
Click here to read

Glatiramer acetate (Copaxone) –induced acute hepatotoxicity in an adolescent with MS

›

VIDEO: TEVA'S DISASTEROUS DROP IN STOCK PRICE:

›
STOCK DOWN 8%: WHAT'S BEHIND TEVA'S MASSIVE PLUNGE?

Momenta overcomes hurdle to launch generic Copaxone and reversed a four month stock slide today after a last-ditch lawsuit by a competitor to stave off generic versions of a multiple sclerosis drug failed - despite that fact that Momenta hasn't revealed when it plans to launch the drug

›
Click here to read

"Ive been on Avonex & Rebif: so 3 times a week I lost a full day afterward due to interferon drugs"

›
Multiple sclerosis has not been an easy road for me Stan. Since being diagnosed with MS in 2004, I have been on two different interfer...

Timothy L. Vollmer, M.D. CURRICULUM VITAE

›
3/13/12 1. Personal history Timothy L. Vollmer, M.D. CURRICULUM VITAE University of Colorado School of Medicine 12631 East 17th Avenue, ...